As more healthcare decision makers (HCDM) across the world review, assess, approve, and implement DTx products, it is important for these clinicians, policy makers, and payors to have access to reliable frameworks that enable more consistent evaluation of DTx products across local, national, and regional settings.
The Digital Therapeutics Alliance (DTA) developed the DTx Value Assessment & Integration Guide to provide the building blocks for DTx product review and economic assessment pathways. This Guide serves as a tool for assessing baseline information about DTx products, their value, and their impact in real-world settings.
The Guide addresses a wide spectrum of HCDM potential considerations across various settings—ranging from individual health systems and employers, to single-payor government systems, and multi-payor public/private settings—and will continue to be updated to ensure ongoing relevance in this quickly evolving ecosystem.
We therefore invite you to provide DTA with insights related to the Guide’s content, utility, implementability, and ongoing development.